1st Quarter - Report

JAMES P. KEESE for TEVA PHARMACEUTICALS USA

Period 1st Quarter 2009 Filed Apr 20, 2009 Signed by James P. Keese, Principal

Official filing
Firm
JAMES P. KEESE
Client
TEVA PHARMACEUTICALS USA
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 515 Patent Reform Act of 2009

Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.

LobbyistCovered position, as disclosed
JAMES P KEESE —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 515 (111th)

Pharmacy PHA

H.R. 1427 Access to Life-Saving Medicine Act, S. 726 Promoting Innovation and Access to Life-Saving Medicine Act), H. R. 1548 Pathway for Biosimilars Act

Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.

LobbyistCovered position, as disclosed
JAMES P KEESE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: S. 726 (111th), H.R. 1427 (111th), H.R. 1548 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.